Combined inhibition of BRAF and MEK in melanoma patients
Mené sur 129 patients atteints d'un mélanome de stade avancé présentant la mutation V600E du gène BRAF, cet essai de phase 1b évalue la dose maximale tolérée et l'activité antitumorale d'un traitement combinant un inhibiteur de BRAF, le vemurafenib, et un inhibiteur de MEK, le cobimetinib
Since BRAF V600 somatic mutations were identified in melanoma, clinical and scientific knowledge has evolved rapidly. Matching patients—particularly those with melanomas harbouring these mutations—to either selective BRAF inhibitors (eg, vemurafenib and dabrafenib) or selective MEK inhibitors (eg, trametinib) has induced considerable clinical benefit. Unfortunately, symptomatic and radiographic responses to these agents fade as resistance evolves. Use of a MEK inhibitor with a BRAF inhibitor co ...
The Lancet Oncology , commentaire, 2013